RISK-FACTORS ASSOCIATED WITH REFRACTORY PEPTIC-ULCERS

被引:68
作者
LANAS, AI [1 ]
REMACHA, B [1 ]
ESTEVA, F [1 ]
SAINZ, R [1 ]
机构
[1] HOSP CLIN UNIV ZARAGOZA,SERV BIOQUIM,UNIDAD MIXTA INVEST,E-50009 ZARAGOZA,SPAIN
关键词
D O I
10.1016/0016-5085(95)90570-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The risk factors associated with refractory peptic ulcers are still undefined. The purpose of this study was to identify these factors in a multivariate context. Methods: Clinical and endoscopic findings as well as Helicobacter pylori status, gastric secretion analysis, serum gastrin levels, nonsteroidal anti-inflammatory drug (NSAID) use, and objective testing of aspirin use by platelet cyclooxygenase activity were studied in 60 consecutive refractory patients with peptic ulcer and 54 matched nonrefractory controls. Results: Refractory patients had a longer history of symptomatic ulcer, had an earlier onset, had more frequent relapses, and smoked more during the episode of refractoriness. H. pylori status was similar in both groups, but H. pylori eradication in a subset of refractory patients (23 of 26) was highly effective in healing these ulcers (14 of 23). Globally, NSAID-analgesic abuse (including >1500 mg/day paracetamol) was present in 40% of refractory patients (P < 0.006). Objective testing showed that 43.7% of NSAID use was surreptitious. Multivariate logistic regression analysis identified only NSAID and analgesic abuse and the number of relapses as individually affecting refractoriness. Conclusions: NSAID and analgesic abuse is the single most important exogenous factor associated with refractoriness. H. pylori infection emerges as an important intrinsic factor, but almost a quarter of refractory patients cannot be linked to either NSAID use or H. pylori infection.
引用
收藏
页码:1124 / 1133
页数:10
相关论文
共 43 条
[1]   PROSPECTIVE MULTICENTER STUDY OF RISK-FACTORS ASSOCIATED WITH DELAYED HEALING OF RECURRENT DUODENAL-ULCERS (RUDER) [J].
ARMSTRONG, D ;
ARNOLD, R ;
CLASSEN, M ;
FISCHER, M ;
GOEBELL, H ;
BLUM, AL .
GUT, 1993, 34 (10) :1319-1326
[2]   OMEPRAZOLE IN THE MANAGEMENT OF REFRACTORY DUODENAL-ULCER [J].
BARDHAN, KD .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :63-75
[3]  
BARDHAN KD, 1984, GUT, V25, P714
[4]  
BARDHAN KD, 1987, TOICS PEPTIC ULCER D, P64
[5]   HELICOBACTER-PYLORI INFECTION IN PEPTIC-ULCER DISEASE [J].
BERSTAD, K ;
BERSTAD, A .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 (07) :561-567
[6]  
BLUM A L, 1990, Gastroenterology, V98, pA22
[7]   THERAPY WITH OMEPRAZOLE IN PATIENTS WITH PEPTIC ULCERATIONS RESISTANT TO EXTENDED HIGH-DOSE RANITIDINE TREATMENT [J].
BRUNNER, G ;
CREUTZFELDT, W ;
HARKE, U ;
LAMBERTS, R .
DIGESTION, 1988, 39 (02) :80-90
[8]   REFRACTORY DUODENAL-ULCERS (NONHEALING DUODENAL-ULCERS WITH STANDARD DOSES OF ANTISECRETORY MEDICATION) [J].
COLLEN, MJ ;
STANCZAK, VJ ;
CIARLEGLIO, CA .
DIGESTIVE DISEASES AND SCIENCES, 1989, 34 (02) :233-237
[9]   EVIDENCE THAT PROSTAGLANDINS DO NOT HAVE A ROLE IN THE CYTOSTATIC ACTION OF ANTI-INFLAMMATORY DRUGS [J].
DEMELLO, MCF ;
BAYER, BM ;
BEAVEN, MA .
BIOCHEMICAL PHARMACOLOGY, 1980, 29 (03) :311-318
[10]   GENOTOXICITY OF ANALGESIC COMPOUNDS ASSESSED BY AN INVITRO MICRONUCLEUS ASSAY [J].
DUNN, TL ;
GARDINER, RA ;
SEYMOUR, GJ ;
LAVIN, MF .
MUTATION RESEARCH, 1987, 189 (03) :299-306